Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 1Nausea 1Gastrointestinal Neoplasms 1

Interventions

Surveys and Questionnaires 9Standard of Care 5Endoscopic Mucosal Resection 5Educational Status 5Blood Specimen Collection 5Diet Therapy 3Referral and Consultation 2Quality of Life 2Practice Guidelines as Topic 2Palliative Care 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Control Groups 2Aprepitant 2Acceptance and Commitment Therapy 2vandetanib 1fosaprepitant 1dolasetron 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Weights and Measures 1Tomography, X-Ray Computed 1Therapeutics 1Surgical Instruments 1Sunitinib 1Sorafenib 1Sampling Studies 1Restraint, Physical 1Remote Patient Monitoring 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Gastrointestinal Neoplasms × dolasetron × Clear all
NCT02550119 2017-03-28

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

University of Southern California

Phase NA Terminated
19 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡